Pcn131 - Assessing the Real-World Cost of Care in Patients With Metastatic Triple Negative Breast Cancer (Mtnbc) in the United States

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.214
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Biology, Metastatic Patterns, and Treatment of Patients With Triple-Negative Breast Cancer

Clinical Cancer Reviews
2009English

Pcn27 - The Real-World Cost and Effectiveness of Everolimus in Metastatic Breast Cancer in the Czech Republic

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Therapy Landscape in Patients With Metastatic HER2-Positive Breast Cancer: Data From the PRAEGNANT Real-World Breast Cancer Registry

Cancers
Cancer ResearchOncology
2018English

Immediate and Long-Term Outcomes of Drug Treatment in Patients With Metastatic Triple Negative Breast Cancer

Malignant tumours
2018English

Phase II and Biomarker Study of Cabozantinib in Metastatic Triple‐Negative Breast Cancer Patients

Oncologist
Cancer ResearchMedicineOncology
2017English

Nab-Paclitaxel for the Management of Triple-Negative Metastatic Breast Cancer

Anti-Cancer Drugs
Cancer ResearchOncologyPharmacology
2015English

The Results of a Study of Chemotherapy With Bevacizumab, Oxaliplatin and Paclitaxel in Patients With Metastatic Triple Negative Breast Cancer

Malignant tumours
2017English

Real World Treatment Patterns of Patients With Ovarian Cancer Receiving First Line Chemotherapy in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

PCN18 Assessing the Clinical and Economic Burden of Veteran Breast Cancer Patients in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy